Divi's Laboratories Limited (BOM:532488)
6,072.60
+69.75 (1.16%)
At close: Jan 22, 2026
Divi's Laboratories Revenue
Divi's Laboratories had revenue of 27.15B INR in the quarter ending September 30, 2025, with 16.12% growth. This brings the company's revenue in the last twelve months to 100.29B, up 16.43% year-over-year. In the fiscal year ending March 31, 2025, Divi's Laboratories had annual revenue of 93.60B with 19.31% growth.
Revenue (ttm)
100.29B
Revenue Growth
+16.43%
P/S Ratio
16.07
Revenue / Employee
9.51M
Employees
10,542
Market Cap
1.61T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 93.60B | 15.15B | 19.31% |
| Mar 31, 2024 | 78.45B | 780.00M | 1.00% |
| Mar 31, 2023 | 77.67B | -11.93B | -13.31% |
| Mar 31, 2022 | 89.60B | 19.90B | 28.56% |
| Mar 31, 2021 | 69.69B | 15.75B | 29.20% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 21.70B |
| Neuland Laboratories | 15.33B |
| Shilpa Medicare | 13.43B |
| Bajaj HealthCare | 6.11B |
| Sudeep Pharma | 5.61B |
| NGL Fine-Chem | 4.08B |
| Gujarat Themis Biosyn | 1.55B |
| Anlon Healthcare | 1.44B |